Clinical Trial Update: Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) [Phase 1]

View source ↗

Summary

Phase 1 RAVE2 trial evaluating 2.0 mg ranibizumab for ischemic central retinal vein occlusion was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion
• Ischemic Central Retinal Vein Occlusion

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: David M. Brown, M.D. | Conditions: Ischemia, Retinal Vein Occlusion | Phase 1 | Status: TERMINATED | Results posted: 2017-08-14